CORDIS
EU research results

CORDIS

English EN

European stem cell consortium for neural cell replacement, reprogramming and functional brain repair

Objective

Neurostemcellrepair aims at taking human stem cells through the final steps toward clinical application in cell replacement therapy for neurological disorders. PD will be taken as the prototypical disease because stem cell therapy is now close to clinical translation. Moreover, we will tackle next generation issues pertaining to stem cells at a basic level and develop new approaches and novel cell sources, validated at pre-clinical stages, for both PD and HD. The project teams represent a wide range of competences, including stem cell specialists, developmental neurobiologists, experts in neurodegeneration, scientists with links to the clinic and stem cell manufacturing/clinical validation. The research plan is constructed on exchange of tools, sharing of protocols and expertise and joint deliverables among the participants. We will address issues related to the control of progenitor proliferation and differentiation into authentic, functional and phenotypically stable dopaminergic or striatal neurons, and exploit new technology for cell reprogramming. We will develop strategies to obtain endurable donor cell engraftment in the host, including acquisition of specific neuronal identities and functional integration in the recipient brain. The therapeutic effect will be evaluated following transplantation in animal models of PD and HD. Cutting edge technologies will be guaranteed by the involvement of three SMEs, one industry and partners experienced in bioengineering, who will collectively provide a toolbox to deliver ontogenetic and reprogramming factors, small molecules and miRNA, immunoseparation strategies, in vivo monitoring of donor cell behaviour, scale up and GMP-compliant protocols. Ultimately, Neurostemcellrepair is expected to develop new cell sources based on cellular reprogramming, make significant advance towards stem cell therapy in HD, and close the gap between development and clinical implementation of stem cell replacement therapies for PD.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI MILANO

Address

Via Festa Del Perdono 7
20122 Milano

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 482 229,07

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

LUNDS UNIVERSITET

Sweden

EU Contribution

€ 564 594

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 485 000

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 523 200

CARDIFF UNIVERSITY

United Kingdom

EU Contribution

€ 492 262

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 246 393

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 416 990

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 438 000

LAVISION BIOTEC GMBH

Germany

INTEGRATED SYSTEMS ENGINEERING SRL

Italy

EU Contribution

€ 180 000

Roslin Cells Ltd.

United Kingdom

EU Contribution

€ 402 451,93

MILTENYI BIOTEC GMBH

Germany

EU Contribution

€ 410 500

LIFE AND BRAIN GMBH

Germany

EU Contribution

€ 358 380

Project information

Grant agreement ID: 602278

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 8 186 684,46

  • EU contribution

    € 6 000 000

Coordinated by:

UNIVERSITA DEGLI STUDI DI MILANO

Italy

This project is featured in...